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background
 
In patients with acute myeloid leukemia (AML) a combination of methods must be used
to classify the disease, make therapeutic decisions, and determine the prognosis. How-
ever, this combined approach provides correct therapeutic and prognostic information
in only 50 percent of cases.
 
methods
 
We determined the gene-expression profiles in samples of peripheral blood or bone
marrow from 285 patients with AML using Affymetrix U133A GeneChips containing
approximately 13,000 unique genes or expression-signature tags. Data analyses were
carried out with Omniviz, significance analysis of microarrays, and prediction analysis
of microarrays software. Statistical analyses were performed to determine the prognos-
tic significance of cases of AML with specific molecular signatures.
 
results
 
Unsupervised cluster analyses identified 16 groups of patients with AML on the basis
of molecular signatures. We identified the genes that defined these clusters and deter-
mined the minimal numbers of genes needed to identify prognostically important clus-
ters with a high degree of accuracy. The clustering was driven by the presence of chromo-
somal lesions (e.g., t(8;21), t(15;17), and inv(16)), particular genetic mutations
(
 
CEBPA
 
), and abnormal oncogene expression (
 
EVI1
 
). We identified several novel clusters,
some consisting of specimens with normal karyotypes. A unique cluster with a distinc-
tive gene-expression signature included cases of AML with a poor treatment outcome.
 
conclusions
 
Gene-expression profiling allows a comprehensive classification of AML that includes
previously identified genetically defined subgroups and a novel cluster with an adverse
prognosis.
abstract
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cute myeloid leukemia (aml) is not
 
a single disease but a group of neoplasms
with diverse genetic abnormalities and var-
iable responses to treatment. Cytogenetics and mo-
lecular analyses can be used to identify subgroups
of AML with different prognoses. For instance, the
translocations inv(16), t(8;21), and t(15;17) herald
a favorable prognosis, whereas other cytogenetic
aberrations indicate poor-risk leukemia.
 
1-5
 
 Abnor-
malities involving 11q23, t(6;9), or 7(q) are defined
as poor-risk markers by some groups
 
2,3
 
 and as in-
termediate-risk markers by others.
 
3-5
 
 These incon-
sistencies and the absence of cytogenetic abnor-
malities in a considerable proportion of patients
argue for refinement of the classification of AML.
Additional reasons for extending the molecular
analyses of AML are exemplified by findings regard-
ing the gene for fms-like tyrosine kinase 3 (
 
FLT3
 
),
the gene encoding ectotropic viral integration 1 site
(
 
EVI1
 
), and the gene for CCAAT/enhancer binding
protein alpha (
 
CEBPA
 
). An internal tandem duplica-
tion in 
 
FLT3,
 
 a hematopoietic growth factor recep-
tor, is the most common molecular abnormality in
AML.
 
6,7
 
 The presence of such mutations in 
 
FLT3
 
 and
elevated expression of the transcription factor EVI1
confer a poor prognosis,
 
6-8
 
 whereas mutations in
 
CEBPA
 
 are associated with a good outcome.
 
9,10
 
Molecular classification based on DNA-expres-
sion profiling offers a powerful way of distinguish-
ing myeloid from lymphoid cancer and subclasses
within these two diseases.
 
11-14
 
 DNA-microarray
analysis has the potential to identify distinct sub-
groups of AML with the use of one comprehensive
assay, to classify cases that currently resist catego-
rization by means of other methods, and to identify
subgroups with favorable or unfavorable prognoses
within genetically defined subclasses. The goals of
this study of 285 adults with AML were to use gene-
expression profiles to identify established and novel
subclasses of AML and otherwise unrecognized cas-
es of poor-risk AML.
 
patients and cell samples
 
Eligible patients had received a diagnosis of primary
AML, which had been confirmed by means of a cy-
tologic examination of blood and bone marrow (Ta-
ble 1). All patients were treated according to the pro-
tocols of the Dutch–Belgian Hematology–Oncology
Cooperative group (available at www.hovon.nl).
 
15-17
 
All subjects provided written informed consent. A
total of 285 patients provided bone marrow aspi-
rates or peripheral-blood samples at the time of
diagnosis and 8 healthy control subjects provided
peripheral-blood samples or bone marrow aspi-
rates. Blasts and mononuclear cells were purified by
Ficoll–Hypaque (Nygaard) centrifugation and cryo-
preserved. CD34+ cells from three control subjects
were sorted by means of a fluorescence-activated
cell sorter. The AML samples contained 80 to 100
percent blast cells after thawing, regardless of the
blast count at diagnosis.
 
isolation and quality control of rna
 
After thawing, cells were washed once with Hanks’
balanced-salt solution. High-quality total RNA was
extracted by lysis with guanidinium thiocyanate fol-
lowed by cesium chloride–gradient purification.
 
18
 
RNA levels, quality, and purity were assessed with
the use of the RNA 6000 Nano assay on the Agilent
2100 Bioanalyzer (Agilent). None of the samples
showed RNA degradation (ratio of 28S ribosomal
RNA to 18S ribosomal RNA of at least 2) or contam-
ination by DNA.
 
gene profiling and quality control
 
Samples were analyzed with the use of Affymetrix
U133A GeneChips. Each gene on this chip is rep-
resented by 10 to 20 oligonucleotides, termed a
“probe set.” The intensity of hybridization of la-
beled messenger RNA (mRNA) to these sets reflects
the level of expression of a particular gene. The
U133A GeneChip contains 22,283 probe sets, rep-
resenting approximately 13,000 genes. We used
10 µg of total RNA to prepare antisense biotinylat-
ed RNA. Single-stranded complementary DNA
(cDNA) and double-stranded cDNA were synthe-
sized according to the manufacturer’s protocol
(Invitrogen Life Technologies) with the use of the
T7-(deoxythymidine)24-primer (Genset). In vitro
transcription was performed with biotin-11-cytidine
triphosphate and biotin-16-uridine triphosphate
(Perkin–Elmer) and the MEGAScript T7 labeling
kit (Ambion). Double-stranded cDNA and comple-
mentary RNA (cRNA) were purified and fragmented
with the GeneChip Sample Cleanup Module (Af-
fymetrix). Biotinylated RNA was hybridized to the
Affymetrix U133A GeneChip (45°C for 16 hours).
Staining, washing, and scanning procedures were
carried out as described in the GeneChip Expres-
sion Analysis technical manual (Affymetrix). All
GeneChips were visually inspected for irregulari-
ties. The global method of scaling, or normaliza-
a
methods
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at ERASMUS UNIVERSITEIT MEDISCH BIBLIO on November 6, 2006 . 
 n engl j med 
 
350;16
 
www.nejm.org april 
 
15, 2004
 
prognostically useful gene-expression profiles in aml
 
1619
 
Glossary
Centroid:
 
 In a self-organizing topologic map of gene expression, the centroid corresponds to the center of a cluster.
 
Chromosomal abnormalities
t(8;21):
 
 One of the commonest cytogenetic abnormalities in AML; produces a hybrid gene by fusing 
 
AML1
 
 on the 
long arm of chromosome 21 with 
 
ETO
 
 on the long arm of chromosome 8.
 
inv(16):
 
 Inversion of a segment of chromosome 16 that produces the 
 
CBF
 
b
 
-MYH11
 
 fusion.
 
t(15;17):
 
 Reciprocal translocation of genetic material between the long arms of chromosomes 15 and 17 that produc-
es the 
 
PML-RAR
 
a
 
 fusion gene, typical of acute promyelocytic leukemia.
 
11q23:
 
 A chromosomal region that becomes rearranged with various partner chromosomal regions in diverse forms 
of leukemia, involving the 
 
MLL
 
 gene.
 
t(6;9):
 
 A rare translocation often found in young patients and sometimes associated with basophilia.
 
¡7(q):
 
 Loss of the long arm of chromosome 7, on monosomy 7.
 
French–American–British (FAB) classification:
 
 An internationally agreed-on method of classifying acute leukemia by 
morphologic means. There are eight subtypes, ranging from M0 (myeloblasts) to M7 (megakaryoblasts).
 
Gene-expression profiling:
 
 Determination of the level of expression of thousands of genes through the use of micro-
arrays. Messenger RNA extracted from the test tissue or cells and labeled with a fluorescent dye is tested for its 
ability to hybridize to the spotted nucleic acids.
 
Microarray or GeneChip: 
 
A robotically spotted array of thousands of complementary DNAs or oligonucleotides.
 
Patient-clustering technique:
 
 A method of grouping patients with similar patterns of gene expression.
 
Pearson’s correlation coefficient:
 
 A statistical measure of the strength of the relationship between variables.
 
Pearson’s Correlation Visualization tool of Omniviz:
 
 Omniviz is a commercial multifunctional statistical package used 
for analysis of microarray data. It allows the visual representation of gene-expression profiles of patients in a 
Pearson’s Correlation View.
 
Prediction analysis of microarrays (PAM):
 
 A statistical technique that identifies a subgroup of genes that best character-
izes a predefined class.
 
Probe set:
 
 A group of 10 to 20 oligonucleotides; each set corresponds to one gene.
 
Significance analysis of microarrays (SAM):
 
 A statistical method used in microarray analyses that identifies genes that 
are significantly differentially expressed between groups of patients on the basis of a change in the level of gene 
expression relative to the standard deviation of repeated measurements.
 
Supervised analysis:
 
 An analysis of the results of microarray profiling that takes external factors into account.
 
Unsupervised analysis:
 
 An analysis of the results of microarray profiling that does not take external factors such as sur-
vival or clinical signs into account.
 
10-Fold cross-validation:
 
 A validation method that works as follows: the model is fitted on 90 percent of the samples, and 
the class of the remaining 10 percent is then predicted. This procedure is repeated 10 times, with each part play-
ing the role of the test samples and the error of all 10 parts added together to compute the overall error. The error 
within the validation set reflects the number of samples wrongfully predicted to be in this set.
 
tion, was applied, and the mean (±SD) difference
between the scaling, or normalization, factors of all
GeneChips (293 samples; 285 from patients with
AML, 5 from subjects with normal bone marrow,
and 3 from subjects with CD34+ cell samples) was
0.70±0.26. All additional measures of quality —
the percentage of genes present (50.6±3.8), the
ratio of action 3' to 5' (1.24±0.19), and the ratio of
 
GAPDH
 
 3' to 5' (1.05±0.14) — indicated a high over-
all quality of the samples and assays. Detailed clin-
ical, cytogenetic, and molecular cytogenetic infor-
mation is available at the Gene Expression Omnibus
(www.ncbi.nlm.nih.gov/geo, accession number
GSE1159).
 
data normalization, analysis, 
and visualization
 
All intensity values were scaled to an average value of
150 per GeneChip according to the method of glob-
al scaling, or normalization, provided in the Affyme-
trix Microarray Suite software, version 5.0 (MAS5.0).
Since our methods reliably identify samples with an
average intensity value of 30 or more but do not re-
liably discriminate values between 0 and 30, these
values were set to 30. This procedure affected 31
percent of all intensity values, of which 64 percent
were flagged as absent by the MAS5.0 software,
3 percent were flagged as marginal, and 33 percent
were flagged as present according to the MAS5.0
software.
For each probe set, the geometric mean of the
hybridization intensities of all samples from the pa-
tients was calculated. The level of expression of each
probe set in every sample was determined relative to
this geometric mean and logarithmically trans-
formed (on a base 2 scale) to ascribe equal weight
to gene-expression levels with similar relative dis-
tances to the geometric mean. Deviation from the
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* All patients with a specific cytogenetic abnormality were included in the analysis, irrespective of the presence of addition-
al abnormalities. A summary of the frequencies and percentages of the cytogenetic and molecular abnormalities for each 
of the assigned clusters can be found in Table Q of Supplementary Appendix 1 (available with the full text of this article 
 
at www.nejm.org). Some samples had more than one abnormality.
 
Table 1. Clinical and Molecular Characteristics of the 285 Patients with Newly Diagnosed AML.
Characteristic Value
 
Sex — no. (%)
Male
Female
137 (48)
148 (52)
Age group — no. (%)
<35 yr
35–60 yr
≥60 yr
76 (27)
177 (62)
32 (11)
Age — yr
Median
Range
44
15–78
White-cell count — ¬10
 
¡3
 
/mm
 
3
 
Median
Range
28
0.3–582
Bone marrow blasts count — %
Median
Range
66
0–98
Platelet count — ¬10
 
¡3
 
/mm
 
3
 
Median
Range
45
3–931
French–American–British classification — no. (%)
M0
M1
M2
M3
M4
M5
M6
Not determined
6 (2)
63 (22)
66 (23)
19 (7)
53 (19)
65 (23)
3 (1)
10 (4)
Cytogenetic abnormalities — no. (%)*
t(15;17)
t(8;21)
inv(16)/t(16;16)
+8
+11
+21
¡5
¡5(q)
¡7
¡7(q)
3q
t(6;9)
t(9;22)
t(11q23)
Complex karyotype (>3 chromosomal abnormalities)
Other abnormal karyotypes
Normal karyotype
Not determined
18 (6)
22 (8)
19 (7)
26 (9)
7 (2)
2 (1)
3 (1)
1 (<1)
13 (5)
7 (2)
6 (2)
4 (1)
2 (1)
19 (7)
11 (4)
60 (21)
119 (42)
10 (4)
Molecular abnormalities — no. (%)
Mutation
 
FLT3
 
 internal tandem duplication
 
FLT3
 
 tyrosine kinase domain
N-
 
RAS
 
K-
 
RAS
CEBPA
 
Overexpression
 
EVI1
 
78 (27)
33 (12)
26 (9)
9 (3)
17 (6)
23 (8)
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geometric mean reflects differential gene expres-
sion. The transformed expression data were sub-
sequently imported into Omniviz software, version
3.6 (Omniviz), significance analysis of microarrays
(SAM) software, version 1.21, and prediction analy-
sis of microarrays (PAM) software, version 1.12.
 
Use of Pearson’s Correlation and Visualization Tool
 
The Omniviz package was used to perform and vi-
sualize the results of unsupervised cluster analysis
(an analysis that does not take into account external
information such as the morphologic subtype or
karyotype). Genes (probe sets) whose level of ex-
pression differed from the geometric mean (reflect-
ing up- or down-regulation) in at least one patient
were selected for further analysis. The clustering of
molecularly recognizable specific groups of patients
was investigated with each of the selected probe
sets with the use of the Pearson’s Correlation and
Visualization tool of Omniviz (provided in Fig. B,
C, D, E, F, G, and H in Supplementary Appendix 1,
available with the full text of this article at www.
nejm.org).
 
The SAM Method
 
All supervised analyses were performed with the use
of SAM software.
 
19
 
 A supervised analysis correlates
gene expression with an external variable such as
the karyotype or the duration of survival. SAM cal-
culates a score for each gene on the basis of the
change in expression relative to the SD of all 285
measurements. The criteria for identifying the top
40 genes for an assigned cluster were a minimal
difference in gene expression between the assigned
cluster and the other AML samples by a factor of
2 and a q value of less than 2 percent. The q value
for each gene represents the probability that it is
falsely called significantly deregulated.
 
The PAM Method
 
All supervised class-prediction analyses were per-
formed by applying PAM software in R (version
1.7.1).
 
20
 
 The method of the nearest shrunken cen-
troids identifies a subgroup of genes that best char-
acterizes a predefined class. The prediction error
was calculated by means of 10-fold cross validation
(see the Glossary) within the training set (two thirds
of the patients) followed by the use of a second val-
idation set (one third of the patients). All genes iden-
tified by the SAM and PAM methods are listed in
Supplementary Appendix 1 (Tables A1 to P1 and R).
 
reverse-transcriptase polymerase chain 
reactions and sequence analyses
 
Reverse-transcriptase–polymerase-chain-reaction
(RT-PCR) assays and sequence analyses for internal
tandem duplication and tyrosine kinase domain
mutations in 
 
FLT3
 
 and mutations in N-
 
RAS, 
 
K-
 
RAS,
 
and 
 
CEBPA,
 
 as well as real-time PCR for 
 
EVI1
 
 were
performed as described previously.
 
8,9,21,22
 
 AML
samples of the clusters characterized by favorable
cytogenetic characteristics (t(8;21), t(15;17), and
inv(16)) were analyzed for the expression of fu-
sion genes by real-time PCR (Supplementary Ap-
pendix 1).
 
statistical analysis
 
Statistical analyses were performed with Stata Sta-
tistical Software, release 7.0. Actuarial probabilities
of overall survival (with failure defined as death from
any cause) and event-free survival (with failure de-
fined as incomplete remission [set at day 1], relapse,
or death during a first complete remission) were es-
timated according to the Kaplan–Meier method.
 
visual correlation of gene expression
 
All specimens of AML were classified into sub-
groups with the use of unsupervised ordering (i.e.,
without taking into account hematologic, cytoge-
netic, or other external information). Optimal clus-
tering of these specimens was reached with the use
of 2856 probe sets (a probe set consists of 10 to 20
oligonucleotides); 2856 sets represent 2008 anno-
tated genes and 146 expressed-sequence tags,
which are short sequences of unknown genes (Fig.
1A and Table 2, and Fig. B, C, D, E, F, G, and H in
Supplementary Appendix 1).
Sixteen distinct groups of patients with AML
were identified on the basis of strong similarities in
gene-expression profiles. Figure 1A, a Pearson’s
correlation view, shows these clusters as red squares
along the diagonal. A red rectangle indicates posi-
tive pairwise correlations (equality in gene expres-
sion between clusters) and a blue rectangle indicates
negative pairwise correlations (inequality in gene ex-
pression between clusters) (Fig. 1A, and Fig. A in
Supplementary Appendix 1). The final Omniviz Cor-
relation View was adapted so that cytologic, cytoge-
netic, and molecular features were plotted directly
adjacent to the original diagonal. This arrangement
allowed the visualization of groups of patients with
results
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similar patterns of gene expression along with rel-
evant clinical and genetic findings (Fig. 1B).
Distinct clusters of t(8;21), inv(16), and t(15;17)
were readily identified with 1692 probe sets (Table
2). Identification of clusters with mutations in 
 
FLT3,
 
monosomy 7, or overexpression of 
 
EVI1
 
 required
2856 probe sets (Table 2, and Fig. B, C, D, E, F, G,
and H in Supplementary Appendix 1). When more
genes were used, the compact pattern of clustering
vanished (Table 2). When included in the Omniviz
Correlation View analyses (2856 probe sets), all five
samples of bone marrow and three CD34+ samples
from control subjects gathered within clusters 8 and
10, respectively.
Genes characteristic of each of the 16 clusters
were obtained by means of supervised analysis (dis-
tinctions on the basis of predefined classes), with
the use of the SAM method. The expression profiles
of the top 40 genes of each cluster are plotted in Fig-
ure 1B beside the correlation view. The SAM analy-
ses identified 599 discriminating genes (Tables A1
to P1 in Supplementary Appendix 1); we were un-
able to identify a distinct gene profile for cluster 14.
 
recurrent translocations
 
CBF
 
b
 
-MYH11
 
All AML samples with inv(16), which causes the
 
CBF
 
b
 
-
 
MYH11
 
 fusion gene, gathered within cluster
9 (Fig. 1B, and Table I in Supplementary Appendix
1). Four specimens within this cluster were not
known to harbor an inv(16), but molecular analysis
and Southern blotting revealed that their leukemic
cells had the 
 
CBF
 
b
 
-
 
MYH11
 
 fusion gene (Table I and
Fig. I in Supplementary Appendix 1). SAM analysis
revealed that 
 
MYH11
 
 was the most discriminative
gene for this cluster (Table I1 and Fig. J in Supple-
mentary Appendix 1). Interestingly, a low level of
expression of 
 
CBF
 
b
 
 was correlated with this cluster,
perhaps because of the decreased expression or de-
letion of the 
 
MYH11
 
-
 
CBF
 
b
 
 alternate fusion gene or
down-regulation of the normal 
 
CBF
 
b
 
 allele by the
CBF
 
b
 
-MYH11 fusion protein.
 
PML-RAR
 
a
 
Cluster 12 contained all cases of acute promyelo-
cytic leukemia (APL) with t(15;17) (Fig. 1B, and Ta-
ble L in Supplementary Appendix 1), including one
patient (Patient 322) who had previously received a
diagnosis of APL with 
 
PML-RAR
 
a
 
 on the basis of
RT-PCR alone. SAM analyses revealed that genes for
hepatocyte growth factor (
 
HGF
 
), macrophage-stim-
 
Figure 1 (facing page). Correlation View of Specimens 
from 285 Patients with AML Involving 2856 Probe Sets 
(Panel A) and an Adapted Correlation View (2856 Probe 
Sets) (Right-Hand Side of Panel B), and the Levels 
of Expression of the Top 40 Genes That Characterized 
Each of the 16 Individual Clusters (Left-Hand Side 
of Panel B).
 
In Panel A, the Correlation Visualization tool displays 
pairwise correlations between the samples. The colors 
of the cells relate to Pearson’s correlation coefficient val-
ues, with deeper colors indicating higher positive (red) 
or negative (blue) correlations. One hundred percent 
negative correlation would indicate that genes with a 
high level of expression in one sample would always have 
a low level of expression in the other sample and vice ver-
sa. Box 1 indicates a positive correlation between clus-
ters 5 and 9 and box 2 a negative correlation between 
clusters 5 and 12. The red diagonal line displays the in-
traindividual comparison of results for a patient with 
AML (i.e., 100 percent correlation). To reveal the patterns 
of correlation, we applied a matrix-ordering method to 
rearrange the samples. The ordering algorithm starts 
with the most highly correlated pair of samples and, 
through an iterative process, sorts all the samples into 
correlated blocks. Each sample is joined to a block in 
an ordered manner so that a correlation trend is formed 
within a block, with the most correlated samples at the 
center. The blocks are then positioned along the diagonal 
of the plot in a similar ordered manner. Panel B shows all 
16 clusters identified on the basis of the Correlation 
View. The French–American–British (FAB) classification 
and karyotype based on cytogenetic analyses are depict-
ed in the columns along the original diagonal of the 
Correlation View; FAB subtype M0 is indicated in black, 
subtype M1 in green, subtype M2 in purple, subtype M3 
in orange, subtype M4 in yellow, subtype M5 in blue, and 
subtype M6 in gray; normal karyotypes are indicated in 
green, inv(16) abnormalities in yellow, t(8;21) abnormal-
ities in purple, t(15;17) abnormalities in orange, 11q23 
abnormalities in blue, 7(q) abnormalities in red, +8 aber-
rations in pink, complex karyotypes (those involving 
more than three chromosomal abnormalities) in black, 
and other abnormalities in gray. 
 
FLT3
 
 internal tandem 
duplication (ITD) mutations, 
 
FLT3
 
 mutations in the 
tyrosine kinase domain (TKD), N-
 
RAS,
 
 K-
 
RAS,
 
 and 
 
CEBPA
 
 mutations, and the overexpression of 
 
EVI1
 
 are 
depicted in the same set of columns: red indicates the 
presence of a given abnormality, and green its absence. 
The levels of expression of the top 40 genes identified 
by the significance analysis of microarrays of each of the 
16 clusters as well as in normal bone marrow (NBM) and 
CD34+ cells are shown on the left side. The scale bar in-
dicates an increase (red) or decrease (green) in the level 
of expression by a factor of at least 4 relative to the geo-
metric mean of all samples. The percentages of the most 
common abnormalities (those present in more than 
40 percent of specimens) and the percentages of 
specimens in each cluster with a normal karyotype 
are indicated.
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ulating 1 growth factor (MST1), and fibroblast
growth factor 13 (FGF13) were specific for this clus-
ter. In addition, cluster 12 could be separated into
two subgroups: one with a high and the other with a
low white-cell count (Fig. K in Supplementary Ap-
pendix 1). This subdivision corresponds to the pres-
ence of FLT3 internal tandem duplication muta-
tions (Fig. 1B).
AML1-ETO
All specimens from patients with the t(8;21) that
generates the AML1-ETO fusion gene grouped with-
in cluster 13 (Fig. 1B, and Table M in Supplementary
Appendix 1). SAM identified ETO as the most dis-
criminative gene for this cluster (Table M1 and Fig.
L in Supplementary Appendix 1).
11q23 abnormalities
Cases with 11q23 abnormalities were scattered
among the 285 samples, although two subgroups
were apparent: cluster 1 and cluster 16 (Fig. 1B, and
Tables A and P in Supplementary Appendix 1).
Cluster 16, with 11 total cases, contained 4 cases of
t(9;11) and 1 case of t(11;19). SAM analyses identi-
fied a strong signature of up-regulated genes in
most cases in this cluster (Fig. 1B, and Table P1 in
Supplementary Appendix 1). Although 6 of 14 cases
within cluster 1 also had 11q23 abnormalities, this
subgroup was more heterogeneous than cluster 16
(Fig. 1B).
cebpa mutations
Mutations in CEBPA occur in approximately 7 per-
cent of patients with AML, most with a normal
karyotype, and predict a favorable outcome.9,10 Two
clusters (4 and 15) had a high frequency of CEBPA
mutations (Fig. 1B). The sets of up-regulated or
down-regulated genes in cluster 4 discriminated
the specimens it contained from those in cluster 15
(Table D1 in Supplementary Appendix 1). The up-
regulated genes included the T-cell genes CD7 and
the T-cell receptor delta locus, which may be ex-
* Two plus signs indicate that 100 percent of specimens were in a single cluster, a single plus sign that specimens were in 
no more than two recognizable clusters, a plus–minus sign that specimens were in more than two recognizable clusters, 
and a minus sign that no clustering occurred. Four patients with AML with abnormalities involving chromosome 5 were 
excluded.
† The factor increase or decrease in the regulation of gene expression is relative to the geometric mean by which the differ-
entially expressed probe sets were selected.
Table 2. Evaluation of the Omniviz Correlation View Results on the Basis of the Clustering of AML Specimens 
with Similar Molecular Abnormalities.*
Variable Distribution
No. of probe sets 147 293 569 984 1692 2856 5071
Factor increase or decrease 
in regulation†
>32 >22.6 >16 >11.3 >8 >5.6 >4
Chromosomal abnormalities
t(8;21) ± + + + ++ ++ +
inv(16) ± ± ± + ++ ++ ++
t(15;17) ± + ++ ++ ++ ++ +
11q23 ± ± ± ± + + ±
¡7(q) ± ± ± ± ± + ±
Mutation
FLT3 internal tandem duplication ± ± ± ± ± ± ±
FLT3 tyrosine kinase domain ¡ ¡ ¡ ¡ ¡ ¡ ¡
N-RAS ¡ ¡ ¡ ¡ ¡ ¡ ¡
K-RAS ¡ ¡ ¡ ¡ ¡ ¡ ¡
CEBPA ¡ ± ± + + + +
Overexpression
EVI1 ¡ ¡ ¡ ¡ ± + ±
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pressed by immature AML cells.23,24 All but one of
the top 40 genes of cluster 15 were down-regulated
(Table O1 in Supplementary Appendix 1). These
genes were also down-regulated in cluster 4 (Fig.
1B). The genes encoding alpha1-catenin (CTNNA1),
tubulin beta-5 (TUBB5), and Nedd4 family interact-
ing protein 1 (NDFIP1) were the only down-regulat-
ed genes among the top 40 in both cluster 4 and
cluster 15.
overexpression of evi1
High levels of expression of EVI1, which occur in
approximately 10 percent of cases of AML, predict
a poor outcome.8 In cluster 10, 10 of 22 specimens
(Table J in Supplementary Appendix 1) showed in-
creased expression of EVI1, and 6 of these 10 speci-
mens had chromosome 7 abnormalities. In cluster
8, 4 of 13 specimens also had chromosome 7 aber-
rations (Table H in Supplementary Appendix 1),
but since its molecular signature differed from that
of cluster 10 (Fig. 1B), the high level of expression
of EVI1 or EVI1-related proteins may have deter-
mined the molecular profile of cluster 10. In the
heterogeneous cluster 1, 5 of 14 specimens also had
increased EVI1 expression. These specimens may
have appeared outside cluster 10 because their mo-
lecular signatures were most likely the result of the
overexpression of EVI1 and an 11q23 abnormality.
flt3 and ras mutations
Samples from most patients in clusters 2, 3, and 6
harbored a FLT3 internal tandem duplication (Fig.
1B). Almost all these patients had a normal karyo-
type. The presence of FLT3 internal tandem duplica-
tion seemed to divide clusters 3, 5, and 12 into two
groups. Other individual specimens with a FLT3 in-
ternal tandem duplication were dispersed over the
entire series; mutations in the tyrosine kinase do-
main of FLT3 were not clustered. Likewise, muta-
tions in codon 12, 13, or 61 of the small GTPase
RAS (N-RAS and K-RAS) had no apparent signa-
tures and did not aggregate in the Correlation View
(Fig. 1B).
other clusters
Specimens from patients with AML with a normal
karyotype clustered into several subgroups within
the assigned clusters (Fig. 1B). Most patients in
cluster 11 had normal karyotypes and no consistent
additional abnormality. Cluster 5 contained mainly
specimens from patients with AML of subtype M4
or M5, according to the French–American–British
(FAB) classification (Fig. 1B). Clusters 7, 8, 11, and
14 were not associated with a FAB subtype but had
distinct gene-expression profiles.
class prediction of distinct clusters
We used the PAM method to validate the cluster-
specific genes identified by the SAM method and to
determine the minimal number of genes that can be
used to predict karyotypic or other genetic abnor-
malities with biologic significance in AML (Table 3).
The 285 specimens were randomly divided into a
training set (189 specimens) and a validation set (96
specimens). All patients in the validation set who
had favorable cytogenetic findings were identified
with 100 percent accuracy with the use of only a few
genes (Table 3). As expected from the SAM analy-
ses, ETO for t(8;21), MYH11 for inv(16), and HGF for
t(15;17) were among the best predictors of the cy-
togenetic abnormalities (Table R in Supplementary
Appendix 1). Cluster 10 (which involved EVI1 over-
expression) was predicted with a high degree of ac-
curacy, although with a higher 10-fold cross-valida-
tion error than that in the groups with favorable
cytogenetic findings. In cluster 16 (involving 11q23
abnormalities), samples from 3 of 96 patients were
wrongfully identified in the validation set. Since
cluster 15 (involving CEBPA mutations) contained
few samples, we combined both CEBPA-containing
clusters. These combined clusters predicted the
presence of CEBPA mutations within the validation
set with 98 percent accuracy. We were unable to
identify a signature that reliably identified FLT3 in-
ternal tandem duplications.
survival analyses
Overall survival, event-free survival, and relapse
rates were determined among patients whose spec-
imens were within clusters containing more than
20 specimens in the Correlation View (clusters 5, 9,
10, 12, and 13) (Fig. 2). The mean (±SE) actuarial
probabilities of overall survival and event-free sur-
vival at 60 months were 59±10 percent and 55±11
percent, respectively, among patients with samples
in cluster 13; 57±12 percent and 47±11 percent, re-
spectively, among those with samples in cluster 12;
and 72±10 percent and 52±10 percent, respective-
ly, among those with samples in cluster 9. Patients
with samples in cluster 5 had an intermediate rate
of overall survival (32±8 percent) and event-free sur-
vival (27±8 percent), whereas survival among pa-
tients with samples in cluster 10 was poorer (the
overall survival rate was 18±9 percent, and the event-
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free survival rate was 6±6 percent), mainly as a re-
sult of an increased incidence of relapse (Fig. 2C).
In this study of 285 patients with AML that was char-
acterized by cytogenetic analyses and extensive mo-
lecular analyses, we used gene-expression profil-
ing to comprehensively classify the disorder. This
method identified 16 groups on the basis of unsu-
pervised analyses involving Pearson’s correlation
coefficient. Our results provide evidence that each
of the assigned clusters represents true subgroups
of AML with specific molecular signatures.
We were able to cluster all cases of AML with
t(8;21), inv(16), or t(15;17), including those that
had not been identified by cytogenetic examination,
into three clusters with unique gene-expression pro-
files. Correlations between gene-expression profiles
and prognostically favorable cytogenetic aberra-
tions have been reported by others,12,13 but we
found that these cases can be recognized with a
high degree of accuracy within a representative co-
hort of patients with AML.
The SAM and PAM methods were highly con-
cordant for the genes identified within the assigned
clusters, indicating that these clusters contained
discriminative genes. For instance, clusters 4 and
15, with overlapping signatures, both included
specimens with normal karyotypes and mutations
in CEBPA. Multiple genes appeared to be down-reg-
ulated in both clusters but were unaffected in any
other subgroup of AML.
The discriminative genes identified by SAM and
PAM may reveal functional pathways that are criti-
cal for the development of AML. These methods of
statistical treatment of the data identified several
genes that are implicated in specific subtypes of
AML, such as the interleukin-5 receptor a (IL5Ra)
gene in AML with t(8;21) abnormalities25 and FLT3-
STAT-5 targets — the gene for interleukin-2 recep-
tor a (IL2Ra)26 and the pim1 kinase gene (PIM1)27
— in AML with FLT3 internal tandem duplication
mutations.
Five clusters (5, 9, 10, 12, and 13) with 20 or
more specimens were evaluated in relation to out-
come of disease. As expected, clusters 9 (involving
CBFb-MYH11), 12 (involving PML-RARa), and 13
(involving AML1-ETO) contained specimens with a
relatively favorable prognosis. 
discussion
* Prediction analysis of microarrays was performed to define the minimal numbers of genes that could predict whether a 
specimen from a particular patient belonged in one of the clusters (first column). The group of patients was randomly 
segregated into a training set (second column) and a validation set (third column). The 10-fold method of cross-valida-
tion, applied on the training set, works as follows: the model is fitted on 90 percent of the samples, and the class of the 
remaining 10 percent is then predicted. This procedure is repeated 10 times, with each part playing the role of the test 
samples and the error of all 10 parts added together to compute the overall error (second column). The minimal num-
bers of probe sets or genes (fourth and fifth columns, respectively) that were identified in the training were tested on the 
validation set (third column). The error within the validation set (third column) reflects the number of samples wrongfully 
predicted in this set. The identities of the probe sets and genes are provided in Table R of Supplementary Appendix 1.
† After randomization none of the patients with CEBPA abnormalities in cluster 15 were included in the validation set.
Table 3. Results of Class Prediction Analysis with the Use of Prediction Analysis of Microarrays.*
Abnormality
Training Set
(N=189)
Validation Set
(N=96)
No. of Probe 
Sets Used
No. of Genes 
Represented
no. of errors
t(8;21), leading to AML1-ETO (cluster 13) 0 0 3 2
t(15;17), leading to PML-RARa (cluster 12) 1 0 3 2
inv(16), leading to CBFb-MYH11 (cluster 9) 0 0 1 1
11q23 (cluster 16) 3 3 31 25
EVI1 (cluster 10) 16 0 28 25
CEBPA (cluster 4) 8 2 13 8
CEBPA (cluster 15) 17 6† 36 32
CEBPA (clusters 4 and 15) 5 2 9 5
FLT3 internal tandem duplication 27 21 56 41
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Specimens in cluster 10 had a distinctly poor out-
come. A randomly selected subgroup of patients
with specimens in this cluster could be identified
with a high degree of accuracy with the use of a min-
imal number of genes. The high frequency of poor
prognostic markers in this cluster (¡7(q), ¡5(q),
t(9;22), or high levels of expression of EVI1) is in ac-
cord with the poor outcome of patients in this clus-
ter. Since this cluster is heterogeneous with regard
to both known poor-risk markers and the presence
or absence of these markers, the molecular signa-
ture of this cluster may signify a biochemical path-
way that causes a poor outcome. The fact that nor-
mal CD34+ cells segregate into this cluster suggests
that the molecular signature of treatment resistance
resembles that of normal hematopoietic stem cells.
The 44 patients with specimens in cluster 5 had
an intermediate duration of survival. Since these
specimens were of the FAB M4 or M5 subtype, it is
possible that genes related to monocytes or macro-
phages were important in the clustering of these
cases.
In three clusters more than 75 percent of speci-
mens had a normal karyotype (clusters 2, 6, and 11).
Most of the patients with specimens in clusters 2 and
6 had FLT3 internal tandem duplication mutations,
whereas patients with specimens in cluster 11,
which had a discriminative molecular signature, did
not have any consistent molecular abnormality.
Clusters 1 and 16 harbored 11q23 abnormalities,
representing defects involving the mixed-lineage
leukemia (MLL) gene. The different gene-expression
profiles of these two clusters are most likely due to
additional distinctive genetic defects. In cluster 1,
this additional abnormality may be a high level of
expression of the oncogene EVI1, which was not ap-
parent in cluster 16. Similarly, distinctive additional
genetic defects may explain the separation of clus-
ters 4 and 15, both of which contained specimens
with CEBPA mutations, clusters 1 and 10, both of
which had high levels of EVI1 expression, and clus-
ters 8 and 10, both of which had a high frequency
of monosomy 7.
Internal tandem duplications in FLT3 adversely
affect the clinical outcome.6,7 The molecular signa-
ture associated with this abnormality is not distinc-
tive; however, the clustering of specimens with these
abnormalities within assigned clusters (e.g., clus-
ter 12) suggests that these internal tandem duplica-
tions result in different biologic entities within the
scope of AML.
Our study demonstrates that cases of AML with
Figure 2. Kaplan–Meier Estimates of Overall Survival 
(Panel A), Event-free Survival (Panel B), and Relapse Rates 
after Complete Remission (Panel C) among Patients 
with AML with Specimens in Clusters 5, 9, 10, 12, and 13.
Cluster 5 was characterized by a French–American–Brit-
ish classification of M4 or M5, cluster 9 by inv(16) ab-
normalities, cluster 10 by a high level of expression of 
EVI1, cluster 12 by t(15;17) abnormalities, and cluster 13 
by t(8;21) abnormalities. P values were calculated with 
the use of the log-rank test.
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known cytogenetic abnormalities and new clusters
of AML with characteristic gene-expression signa-
tures can be identified with the use of a single assay.
The applicability and performance of genome-wide
analysis will advance with the availability of novel
whole-genome arrays, improved sequence annota-
tion, and the development of sophisticated proto-
cols and software, allowing the analysis of subtle
differences in gene expression and predictions of
pathogenic pathways. 
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